Similarly, in a phase I/II clinical trial, Turtle et al. showed that CD-19 CAR-T cells therapy was clinically successful in 71% of patients experiencing high-risk CLL, which progressed after ibrutinib treatment [116], a Bruton’s tyrosine kinase inhibitor initially approved as first-line therapy for r/r CLL [117]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.